Effect of a carbohydrate rich diet in vas deferens contractility in rats

Abstract

Objective: We aimed to investigate the effects of a Carbohydrate-rich diet on vas deferens contractility and histology.

Materials and Methods: Twenty mature male rats were subjected into two groups. The control group received regular food and water and the study group received regular food and a carbohydrate-rich liquid diet mixture of 37–40% fructose, 30–36% sucrose and 27–30% glucose instead of water and prepared stock diet was diluted with 50% water. Animals were weighted and sacrificed after six weeks and the vas deferens has been evaluated with in vitro studies. Five rats from both the control and study groups, were separated into subgroups for dapoxetine administration 4 hours before they were sacrificed.

Results: At the beginning of this study, the mean body weights were 228.6±6.7 g (range: 205-237) and 231.4±9.6 g (range: 202-243) in control and study groups, respectively. The mean body weights were 247.1±4.8 g (236-252) in the control group and 318.8±9.3 g (314-326) in the study group (p<0.001). Weight gain was more distinct in the study group when compared to control group (p<0.001) (9% vs 27.4%). Contractile responses were recorded in each group, including the dapoxetine subgroups, to various noradrenaline concentrations; all groups had similar results (p>0.05). Responses to Adenosine Three Phosphate (ATP) were also not significant (p>0.05). The contractile responses at the same frequencies of electrical field stimulation (EFS) were similar in both groups (p>0.05). Histological examinations showed no abnormalities in either group.

Conclusion: Carbohydrate-rich diet caused no increase in fibrotic activity, and pharmacological and histological properties remained stable, but caused significant weight gain over a short time period. Furthermore, dapoxetine had no effect on the contractility of the vas deferens. 

Keywords

• Dapoxetine,Fructose; Obesity; Vas deferens

Effect of a carbohydrate rich diet in vas deferens contractility in rats

Öz

Kaynakça

1. Wang YC, Pamplin J, Long MW, Ward ZJ, Gortmaker SL, Andreyeva T. Severe Obesity In Adults Cost State Medicaid Programs Nearly $8 Billion In 2013. Health Aff (Millwood). 2015 Nov 1;34(11):1923-31. doi: 10.1377/hlthaff.2015.0633.
2. Llewellyn A, Simmonds M, Owen CG, Woolacott N. Childhood obesity as a predictorof morbidity in adulthood: a systematic review and meta-analysis. ObesRev. 2015 Oct 6. doi: 10.1111/obr.12316.
3. Rowland DL, et al. The psychological burden of premature ejaculation. J Urol 2007;177(3):1065-70.
4. Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J. The premature ejaculation prevalence andattitutes (PEPA) survey: Prevalence, comorbidities, and professional help-seeking. EurUrol 2007;51:816-823.
5. Mauro G, Vincenzo F, Arcangelo S, Giovanni C, Sergio S, Shahrokh FS, Mario M, Filiberto Z, Marco C and Giacomo N. Impact of Medical Treatments for Male Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia on Ejaculatory Function: A SystematicReview and Meta-Analysis. 2014 June 11;6:1554-1566.
6. Shamloul R, el-Nashaar A. Chronic prostatitis in premature ejaculation: a cohort study in 153 men. J Sex Med. 2006; 3:150-154.
7. Laumann EO, et al. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999 281(6):537-44.
8. Ferguson DR, Kennedy I, Burton TJ. ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes—a possible sensory mechanism? J Physiol. 1997;505:503-511.

9. Driessen B, von K, I, Starke K. Pl-purinoceptor-mediated modulation of neural noradrenaline and ATP release in guinea-pig vas deferens. Naunyn Schmiedebergs Arch Pharmacol 1994;350:42-48.
10. Fukumitsu A, Takano Y, Iki A, Honda K, Saito R, Katsuragi T, Kamiya H. Endogenous ATP released by electrical field stimulation causes contraction via P2X and P2Y purinoceptors in the isolated tail artery of rats. Jpn J Pharmacol. 1999;81:375-380.
11. Salas-Salvadó J, Bulló M, Pérez-Heras A, Ros E. Dietary fibre, nuts and cardiovascular diseases. British Journal of Nutrition. 2006 Nov 1;96(S2):S45-51.
12. Corn Refiners Association. Report on HFCS Consumption. Washington, 2013.
13. Crapo PA, Kolterman OG, Olefsky JM. Effects of oral fructose in normal, diabetic, and impaired glucose tolerance subjects. Diabetes Care. 1980;3:575-582.
14. Hassinger W, Gaberle E, Schultz G, et al. Blood glucose levels and insulin requirement after fructose as sweetener in diabetic diet. Diabetologia1980;19:281.
15. Gaby AR. Alternative Medicine Review 2005;10(4):294-306.
16. Elliott SS, Keim NL, Stern JS, et al. Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr 2002;76:911-922.
17. Bantle JP, Laine DC, Thomas JW. Metabolic effects of dietary fructose and sucrose in types I and II diabetic subjects. JAMA 1986;256:3241-3246.
18. Kawasaki T, Ogata N, Akanuma H, et al. Postprandial plasma fructose level is associated with retinopathy in patients with type 2 diabetes. Metabolism 2004;53:583-588.
19. Cummings JM, Rodning CB. Urinary stress incontinence among obese women: review of pathophysiology therapy. Int Urogynecol J Pelvic Floor Dysfunct 2000;11:41-4.
20. Yoshida M, Yamaguchi O. Detrusor Underactivity: The Current Concept of the Pathophysiology. Low Urin Tract Symptoms. 2014;6(3):131-7. doi: 10.1111/luts.12070.
21. Medina P, Segarra G, Mauricio MD, et al. Role of Ca(2+)-activated K(+) channels and Na(+), K(+)-ATPase in prostaglandin E(1)- and E(2)- induced inhibition of the adrenergic response in human vas deferens. Biochem Pharmacol 2011; 82(1):65–71.
22. Burnstock G, Verkhratsky A. Vasdeferens–a model used to establish sympathetic cotransmission. Trends Pharmacol Sci 2010;31(3):131–9 PubMed PMID: 20074819.
23. Saad F, Gooren LJ. The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. Journal of obesity. 2010 Aug 10;2011.
24. Basiri A, Ghaed MA, Simforoosh N, et al. Is modified retroperitoneal lymph node dissection a live for clinical stage I non-seminomatous germ cell testicular tumor Urol J. 2013;10(2):873–7.
25. Nishizawa Y, Ito M, Saito N, et al. Male sexual dysfunction after rectal cancer surgery. Int J Colorectal Dis 2011;26(12):1541–8.
26. May AG, DeWeese JA, Rob CG. Changes in sexual function following operation on the abdominal aorta. Surgery 1969;65(1):41–7.
27. Aasvang EK, Kehlet H. Post herniotomy dysejaculation: successful treatment with mesh removal and nerve transection. Hernia 2008;12(6):645–7.
28. Orasanu B, Frasure H, Wyman A, et al. Sexual dysfunction in patients with multiple sclerosis. Mult Scler Relat Disord 2013;2:117–23.
29. Scott TF, Frohman EM, De Seze J, et al. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011;77(24):2128–34.
30. Kamenov ZA, Traykov LD. Diabetic autonomic neuropathy. Adv Exp Med Biol 2012;771:176–9.
31. Brown DJ, Hill ST, Baker HW. Male fertility and sexual function after spinal cordinjury. Prog Brain Res 2006;152:427–39.
32. Carson C, Gunn, K. Premature ejaculation: definition andprevalence. Int J Impot Res 18 Suppl 1, S5–13.
33. De Hong C, Ren LL, Yu H, Qiang W. The role of dapoxetine hydrochloride on-demand for the treatment of men with premature ejaculation. Scientific reports. 2014 Dec 1;4:7269.
34. Maciel LC, Glina S, Palma PC, Costa NF, Netto NR. Histopathological alterations of the vas deferens in rats exposed to polypropylene mesh. BJU international. 2007 Jul 1;100(1):187-90.